Synthesis and biological evaluation of new antitubulin agents containing 2-(3?,4?,5?-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine scaffold by Romagnoli, Romeo et al.
molecules
Article
Synthesis and Biological Evaluation of New
Antitubulin Agents Containing 2-(3′,4′,5′-
trimethoxyanilino)-3,6-disubstituted-4,5,6,7-
tetrahydrothieno[2,3-c]pyridine Scaffold
Romeo Romagnoli 1,* , Filippo Prencipe 1, Paola Oliva 1, Barbara Cacciari 1, Jan Balzarini 2,
Sandra Liekens 2, Ernest Hamel 3, Andrea Brancale 4, Salvatore Ferla 4, Stefano Manfredini 5 ,
Matteo Zurlo 5 , Alessia Finotti 5 and Roberto Gambari 5,6
1 Dipartimento di Scienze Chimiche e Farmaceutiche, University of Ferrara, Via L. Borsari 46, 44121 Ferrara,
Italy; prnfpp@unife.it (F.P.); lvopla@unife.it (P.O.); ccb@unife.it (B.C.)
2 Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, B-3000 Leuven,
Belgium; jan.balzarini@rega.kuleuven.be (J.B.); sandra.liekens@kuleuven.be (S.L.)
3 Screening Technologies Branch, Developmental for Cancer Research, National Cancer Institute, National
Institute of Health, Frederick, MD 21702, USA; hamele@dc37a.nci.nih.gov
4 School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10
3NB, UK; brancalea@cardiff.ac.uk (A.B.); ferlas1@cardiff.ac.uk (S.F.)
5 Dipartimento di Scienze della Vita e Biotecnologie, Università di Ferrara, 44121 Ferrara, Italy;
stefano.manfredini@unife.it (S.M.); matteo.zurlo@unife.it (M.Z.); alessia.finotti@unife.it (A.F.);
roberto.gambari@unife.it (R.G.)
6 Interuniversity Consortium for Biotechnology, Area di Ricerca, Padriciano, 34149 Trieste, Italy
* Correspondence: rmr@unife.it; Tel.: +39-0532-455303
Received: 15 March 2020; Accepted: 4 April 2020; Published: 7 April 2020


Abstract: Two novel series of compounds based on the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine
and 4,5,6,7-tetrahydrobenzo[b]thiophene molecular skeleton, characterized by the presence of a
3′,4′,5′-trimethoxyanilino moiety and a cyano or an alkoxycarbonyl group at its 2- or 3-position,
respectively, were designed, synthesized, and evaluated for antiproliferative activity on a panel of
cancer cell lines and for selected highly active compounds, inhibition of tubulin polymerization, and
cell cycle effects. We have identified the 2-(3′,4′,5′-trimethoxyanilino)-3-cyano-6-methoxycarbonyl-
4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivative 3a and its 6-ethoxycarbonyl homologue 3b as new
antiproliferative agents that inhibit cancer cell growth with IC50 values ranging from 1.1 to 4.7 µM
against a panel of three cancer cell lines. Their interaction with tubulin at micromolar levels leads to
the accumulation of cells in the G2/M phase of the cell cycle and to an apoptotic cell death. The cell
apoptosis study found that compounds 3a and 3b were very effective in the induction of apoptosis in a
dose-dependent manner. These two derivatives did not induce cell death in normal human peripheral
blood mononuclear cells, suggesting that they may be selective against cancer cells. Molecular
docking studies confirmed that the inhibitory activity of these molecules on tubulin polymerization
derived from binding to the colchicine site.
Keywords: microtubules; structure–activity relationship; antiproliferative activity; tubulin;
tetrahydrothieno[2,3-c]pyridine
1. Introduction
Cancer, which is the result of deviation of cell growth control mechanisms, has become a major
worldwide disease and the second leading cause of mortality in developed countries, with almost 20
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million deaths annually [1,2]. Many of the current treatments, involving an integrated treatment of
surgery, radiation, and chemotherapy, have problems with toxicity and drug resistance [3,4]. Therefore,
there is a strong demand for the discovery and development of effective chemotherapeutic agents with
high selectivity and low toxicity [5–7].
The central role of microtubules in cell division and mitosis makes them an important target for the
development of potential new anticancer agents [8–10]. A large number of small molecules displaying
wide structural diversity and derived from natural sources or obtained by chemical synthesis have been
identified within the last several decades [11–13] and have been shown to interfere with microtubules,
polymeric structures composed of α- and β-tubulin heterodimers [14–16].
Prominent examples of tubulin-binding compounds used clinically for cancer treatment include
microtubule-stabilizers that inhibit microtubule function by promoting abnormally high levels of
tubulin polymerization. Examples of such drugs include paclitaxel (Taxol) and its semisynthetic
analogue docetaxel (Taxotere) [17,18]. In contrast, the vinca alkaloids vincristine, vinorelbine, and
vinblastine destabilize microtubules and act as microtubule depolymerizers by inhibiting tubulin
polymerization [19]. Both taxoids and vinca alkaloids interact with β-tubulin, but at different sites,
named the taxol and vinca sites, respectively [20]. The colchicine-site binders that inhibit tubulin
assembly [21] are another class of compounds in discovery and development, including combretastatin
A-4 phosphate (CA-4P) [22], that bind to the colchicine site located between the α- and β-tubulin
subunits in the heterodimer, distinct from the vinca site located between adjacent α- and β-tubulin
heterodimers [23].
Although many chemically diverse synthetic tubulin inhibitors have been synthesized, there
is still a need to identify novel small molecules that target microtubules [24–28]. Among
such compounds, thiophene [29–34] and fused thiophenes such as benzo[b]thiophenes [35–40],
thieno[3,2-d]pyrimidines [41–43], and thieno[2,3-b]pyridines [44] were present as molecular skeletons
in a significant number of synthetic inhibitors of microtubule polymerization, but there are limited
examples of small molecules showing interesting activities in inhibiting both microtubule assembly
and cell proliferation based on the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine molecular skeleton as the
core structure.
In an earlier published study, a series of molecules with general structure 1 (Figure 1), based on
the 2-amino-3-(3′,4′,5′-trimethoxybenzoyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine skeleton, yielded
the promising derivatives 1a and 1b. These compounds inhibit cancer cell growth with IC50 values
ranging from 25 to 440 nM against a panel of four cancer cell lines and exert strong inhibition of tubulin
polymerization by binding to the colchicine site of tubulin [45]. For this series of molecules, the presence
of a N-methoxy/ethoxycarbonyl moiety at the 6-position of the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine
system was needed for potent antiproliferative activity.
A second series of compounds with general structure 2, reported by Beckers et al. [46,47],
incorporated the 2-carboxamido-3-cyano-4,5,6,7-tetrahydrothieno[2,3-c]pyridine system, and these
agents were active at micromolar concentrations (IC50 = 0.2–5 µM) as antiproliferative agents against
human colon adenocarcinoma (RKOp27) cells. Bausch et al. [48] reported a molecule named 4SC-207
(2a), characterized by the presence of the 2-[(pyridin-3′-yl)acrylamido]-3-cyano-4,5,6,7-tetrahydrothieno
[2,3-c]pyridine skeleton, able to inhibit microtubule polymerization at high concentrations and showing
strong antiproliferative activity at low nanomolar concentrations in a large panel of cancer cell
lines. These studies [46–48] showed that the presence of a cyano group at the 3-position of the
4,5,6,7-tetrahydrothieno[2,3-c]pyridine nucleus was required for antiproliferaive activity. These
findings prompted us to analyze this class of compounds in more detail.
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Figure 1. Structures of tetrahydrothieno[2,3-c]pyridines 1–3. Compounds with a 3,4,5-trimethoxyphenyl
moiety, such as colchicine, CA-4, podophyllotoxin, and poly-methoxychalcone.
Building upon these observations, since the 6-N-alkoxycarbonyl-4,5,6,7-tetrahydrothieno[2,3-c]
pyridine structure was demonstrated to be essential for bioactivity, we retained this pharmacophoric
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unit throughout the present investigation and kept the 3-cyano group in compounds we synthesized.
We were intrigued by the idea of studying the biological effects of replacing the carboxamido group at
the 2-position of the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine ring of compounds with general structure 2
with a 3′,4′,5′-trimethoxyanilino moiety to yield the 2-(3′,4′,5′-trimethoxyanilino)-3-cyano-6-methoxy/
ethoxycarbonyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridines 3a and 3b. Previous studies have shown
that the 3,4,5-trimethoxyphenyl moiety is a pharmacophoric group that is an essential structural
requirement for the anticancer effect of numerous inhibitors of tubulin polymerization, such as
colchicine, combretastatin A-4 (CA-4), podophyllotoxin, and poly-methoxychalcone [49,50]. Starting
from compounds 3a and 3b, additional analogues were also generated by modification of the 3-cyano
function of the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine skeleton. The cyano group was replaced
with a 3-alkoxycarbonyl moiety, such as 3-methoxycarbonyl (3c–3e), 3-ethoxycarbonyl (3f–3h), or
3-tert-butoxycarbonyl (3i–3j). Moreover, the influence on antiproliferative activity of the substituent
(R2) at the 6-position was evaluated with R2 as acetyl or methoxy/ethoxycarbonyl.
Additional structural modifications involved the nitrogen at the 6-position of 4,5,6,7-tetrahydrothi
eno[2,3-c]pyridine scaffold, by the classical bioisosteric replacement with a CH group to furnish a novel
series of 2-(3′,4′,5′-trimethoxyanilino)-3,6-substituted-4,5,6,7-tetrahydrobenzo[b]thiophene derivatives
3k–3p. For this latter series of compounds, besides the C-3 cyan and methoxy/ethoxycarbonyl moieties,
the substituents examined at the C-6 position were methyl (3k, 3m, and 3o) and phenyl (3l, 3n, and
3p) groups.
2. Chemistry
The 2-(3′,4′,5′-trimethoxyanilino)-3-cyano/alkoxycarbonyl-6-substituted-4,5,6,7-tetrahydrothieno
[2,3-c]pyridines 3a–3j and the corresponding 4,5,6,7-tetrahydrobenzo[b]thiophenes 3k–3p were
prepared through the three-step procedure shown in Scheme 1.
Scheme 1. Synthesis of compounds 3a-p. Reagents. a: appropriate ketone (4-methyl/phenylcyclohexan
one, N-acetyl-4-piperidone, or methoxy/ethoxycarbonyl-4-piperidone), malonitrile or methyl/ethyl/t-
butylcyanoacetate, S8, TEA, MeOH or EtOH, reflux; b: t-BuONO, CuBr2, CH3CN, 65 ◦C; c: 3,4,5-
trimethoxyaniline, Pd(OAc)2, BINAP, Cs2CO3, PhMe, 100 ◦C, 18 h.
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The one-pot Gewald reaction [51] applied to commercially available 4-methyl/phenylcyclohe
xanone, N-acetyl-4-piperidone or methoxy/ethoxycarbonyl-4-piperidone with an activated nitrile
(malonitrile or a cyanoacetate, such as methyl/ethyl/t-butylcyanoacetate) and elemental sulfur
in refluxing methanol or ethanol in the presence of triethylamine (TEA) as base furnished
2-amino-3-cyano/ alkoxycarbonyl-6-substituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridines 4a–4j and
the related 4,5,6,7-tetrahydrobenzo[b]thiophene analogues 4k–4p. These latter compounds were
transformed by substitutive deamination with tert-butyl nitrite (t-BuONO) and copper (II)
bromide (CuBr2) in acetonitrile into the 2-bromo-4,5,6,7-tetrahydrothieno[2,3-c]pyridines 5a–5j and
4,5,6,7-tetrahydrobenzo[b]thiophene analogues 5k–5p, respectively [52]. Finally, the novel 2-(3′,4′,5′-
trimethoxyanilino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridines 3a–3j and 2-(3′,4′,5′-trimethoxyanilino)-
4,5,6,7-tetrahydrobenzo[b]thiophenes 3k–3p were prepared in good yields by palladium-catalyzed
arylamination conditions of the appropriate 2-bromo-4,5,6,7-tetrahydrothieno[2,3-c]pyridine
5a-j and 2-bromo-4,5,6,7-tetrahydrobenzo[b]thiophene analogues 5k–5p, respectively, with
3,4,5-trimethoxyaniline in the presence of palladium (II) acetate (Pd(OAc)2), rac-2,2′-bis-(diphenylpho
sphane)-1,1′-binaphtyl (BINAP), and cesium carbonate (Cs2CO3) (as catalyst, ligand, and base,
respectively) in toluene [53].
3. Results and Discussion
3.1. In Vitro Antiproliferative Activities Against A Panel of Three Different Cancer Cell Lines (L1210, CEM,
and HeLa)
In Table 1 we report the in vitro antiproliferative activity of 2-(3′,4′,5′-trimethoxyanilino)-4,5,6,7-
tetrahydrothieno[2,3-c]pyridine derivatives 3a–3j and the related 4,5,6,7-tetrahydrobenzo[b]thiophenes
3k–3p against a panel of three cell lines, which were derived from different cancer types, including
murine leukemia (L1210), human T-lymphoblastoid leukemia (CEM), and human cervix carcinoma
(HeLa) cells. CA-4 and 2-carboxamido-3-cyano-6-ethoxycarbonyl-4,5,6,7-tetrahydrothieno[2,3-c]pyri
dine 2b used in Beckers’ study [46,47] were also used as positive controls. All compounds that had an
IC50 > 20 µM are considered inactive for purposes of this discussion.
Compound 3b with an ethoxycarbonyl substituent at the C-6 position of the 2-(3′,4′,5′-trimethoxy
anilino)-3-cyano-4,5,6,7-tetrahydrothieno[2,3-c]pyridine system, along with its 6-methoxycarbonyl
analogue 3a, exhibited the greatest antiproliferative activity among the tested compounds, with
IC50 values of 1.1–2.8 and 1.9–4.7 µM, respectively, showing improved activity against HeLa cells as
compared with the other two cell lines. The 3-cyano-6-ethoxycarbonyl-4,5,6,7-tetrahydrothieno[2,3-
c]pyridine derivative 3b possessed the highest potency, inhibiting the growth of L1210, CEM, and
HeLa cells with IC50 values of 2.8, 2.3, and 1.1 µM, respectively. These values are 1.5-fold lower
than those obtained with the 6-methoxycarbonyl derivative 3a against L1210 and HeLa cells, while
both compounds were equipotent against CEM cells. The activities of 2-(3′,4′.5′-trimethoxyanilino)
derivatives 3a and 3b were quite similar to that of 2-(thiophene-2′-carboxamido) analogue 2b against
L1210 and CEM cells, while there was greater difference with the HeLa cell line, with compounds 3a
and 3b 40- and 20-fold more active than 2b (IC50: 41 µM). However, CA-4 was more potent than any of
the new compounds in all cell lines examined. The activity of the most effective compounds (3a and
3b) was also evaluated on the human chronic myelogenous leukemia K562 cell line. The data obtained
demonstrated that both 3a and 3b were highly efficient in inhibiting K562 cells, displaying IC50 values
of 0.75 and 0.70 µM, respectively.
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Table 1. In vitro growth inhibition activity of compounds 3a–3p and reference compounds 2b and
CA-4 against the proliferation of murine leukemia (L1210), human T-lymphocyte (CEM), and human
cervix carcinoma (HeLa) cells.
IC50 (µM) a
Compound L1210 CEM HeLa
3a 4.7 ± 0.4 2.9 ± 2.1 1.9 ± 1.2
3b 2.8 ± 2.3 2.3 ± 1.7 1.1 ± 0.0
3c 17 ± 5 16 ± 4 23 ± 10
3d 15 ± 2 12 ± 4 16 ± 3
3e 26 ± 2 43 ± 12 48 ± 17
3f 22 ± 4 22 ± 8 67 ± 20
3g 19 ± 0 19 ± 1 19 ± 4
3h 25 ± 3 34 ± 9 24 ± 3
3i 18 ± 3 20 ± 2 14 ± 1
3j 19 ± 3 19 ± 2 20 ± 4
3k >250 >250 202 ± 25
3l 92 ± 29 58 ± 53 124 ± 8
3m 82 ± 13 45 ± 17 11 ± 6
3n 101 ± 9 102 ± 50 48 ± 6
3o 86 ± 41 78 ± 33 66 ± 6
3p 112 ± 1 88 ± 12 169 ± 18
2b 6.0 ± 0.3 3.7 ± 1.2 41 ± 27
CA-4 (nM) 2.8 ± 1.1 1.9 ± 1.1 4.1 ± 0.1
a IC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean
± SE from the dose-response curves of at least three independent experiments.
The C-3-position of the 2-(3′,4′,5′-trimethoxyanilino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine
nucleus plays an essential role in the antiproliferative activity of derivatives 3a–3j. The activity
of compounds 3a and 3b demonstrated that the 3-cyano substitution was crucial for potent cell growth
inhibition. Its substitution with an alkoxycarbonyl moiety led to a reduction of growth inhibition
activity (compare 3a with 3c, 3f, and 3i as well as 3b with 3d, 3g, and 3j). For the most active
compound of the series (3b), replacement of the 3-cyano group with alkoxycarbonyl moieties, such as
methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl (compounds 3d, 3g, and 3j, respectively)
reduced antiproliferative activity from 5- to 18-fold against the three cancer cell lines.
Finally, although only a few compounds were synthesized thus far in the 4,5,6,7-tetrahydrobenzo
[b]thophene series, all compounds of this series proved inactive (IC50 >50 µM), significantly less
potent than the corresponding 4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivatives. The reduced
antiproliferative activity of the 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives as compared with the
4,5,6,7-tetrahydrothieno[2,3-c]pyridine compounds demonstrates that the presence of a piperidine ring
fused with the thiophene scaffold is critical for activity.
In order to investigate the selective antiproliferative activities of derivatives 3a and 3b in normal
human cells, both these molecules were tested in vitro against human peripheral blood mononuclear
cells (PBMC) isolated from healthy donors. After treatment of both resting and phytohemagglutin
(PHA)-stimulated PBMC for 72 h, the IC50 values were over 20 µM, indicating that 3a and 3b did not
substantially affect the viability of these cells, suggesting that these two compounds have cancer cell
selective killing properties.
3.2. Inhibition of Tubulin Polymerization and Colchicine Binding
To investigate whether the antiproliferative activities of these compounds were related to an
interaction with the microtubule system, the two most active compounds of the series (3a and 3b) as
antiproliferative agents were evaluated for their inhibitory effects on tubulin polymerization and on
the binding of [3H]colchicine to tubulin (in the latter assay, tubulin was examined at a concentration
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of 1 µM, while compounds and colchicine were at 5 µM). For comparison, CA-4 was examined in
contemporaneous experiments as a reference compound (Table 2). Derivatives 3a and 3b inhibited
the assembly reaction with IC50 values of 3.6 and 3.8 µM, respectively, considerably higher than the
value obtained with CA-4 (IC50: 0.54 µM), which is consistent with the reduced antiproliferative
activity of 3a and 3b with respect to CA-4. These results indicated that tubulin may be the intracellular
target of compounds 3a and 3b. In competition experiments, both these compounds inhibited the
binding of [3H]colchicine to its binding site on tubulin, with 31% and 29% of inhibition, respectively.
These derivatives were less potent than CA-4, which in these experiments inhibited colchicine binding
by 98%.
Table 2. Inhibition of tubulin polymerization and colchicine binding by compounds 3a, 3b, and CA-4.
Compound Tubulin assembly
a
IC50 ± SD (µM)
Colchicine binding b
% ± SD
3a 3.8 ± 0.05 29 ± 1
3b 3.4 ± 0.05 31 ± 1
CA-4 0.54 ± 0.06 98 ± 0.9
a Inhibition of tubulin polymerization. Tubulin was at 10 µM. b Inhibition of [3H]colchicine binding. Tubulin,
colchicine, and tested compound were at 1, 5, and 5 µM, respectively.
The results are consistent with the conclusion that the antiproliferative activity of these compounds
derives from an interaction with the colchicine site of tubulin and interference with microtubule
assembly. In conclusion, manipulation of the scaffold of compounds with general structures 1 and
2 led to the successful identification of a new series of inhibitors of tubulin assembly, characterized
by a 3,4,5-trimethoxy aniline and a cyano function at the 2- and 3-positions, respectively, of the
4,5,6,7-tetrahydrothieno[2,3-c]pyridine nucleus.
3.3. Analysis of Effects on the Cell Cycle
Since molecules exhibiting effects on tubulin assembly should cause alteration of cell cycle
parameters, leading to a preferential G2/M blockade, the effects of compounds 3a and 3b on cell cycle
distribution were investigated on K562 cells using flow cytometry. The cells were cultured for 72
h in the presence of two different concentrations (IC50 and IC75) for each tested derivative and the
obtained results were compared with non-treated K562 cells as control. Both compounds caused a
significant (p < 0.01) and dose-dependent accumulation of the cells in the G2/M phase of the cell
cycle, with a concomitant decrease of cells in the other phases of the cell cycle (especially the G0/G1
phase). As shown in Figure 2 (panels I and L), treatment of K562 cells at different concentrations of 3b
(IC50: 0.70 µM and IC75: 0.90 µM) increased the percentage of G2/M-phase cells from 22.9% ± 0.7%
(control group) to 30.3% ± 1.3% and 33.5% ± 0.6% respectively, indicating that compound 3b impact
the cell cycle distribution in a dose-dependent manner. Similarly, for derivative 3a (IC50: 0.75 µM and
IC75: 1.0 µM), an increase of the percentage of G2/M-phase cells from 22.2% ± 0.7% (control group) to
33.6% ± 1.1%, and 34.9% ± 1.3% was observed at the values, respectively. These data confirm that
compounds 3a and 3b act selectively on the G2-M phase of the cell cycle, as expected for inhibitors of
tubulin assembly.
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Figure 2. Effects of the tetrahydrothieno[2,3-c]pyridines 3a and 3b on cell growth and cell cycle.
K562 cells were treated with compounds 3a (A,C–E,I) and 3b (B,F–H,L) and the following biological
parameters were evaluated: cell growth (A,B) and cell cycle distribution (C–H). Analyses were
performed after 3 days of cell culture at the indicated concentrations of the compounds. In panels C-H,
representative cell cycle analyses are reported. In panels I and L, a summary of three independent
experiments is reported. The data represent the average ± S.D. *: significant (p < 0.05); **: highly
significant (p < 0.01).
3.4. Effects on Apoptosis
In order to characterize the mode of cell death induced by compounds 3a and 3b, a biparametric
flow cytometry analysis was performed using propidium iodide (PI), which stains DNA and is
permeable only to dead cells, and fluorescent immunolabeling of the protein annexin-V, which binds
to the phospholipid phosphatidylserine (PS) in a highly selective manner. This phospholipid flips
from the inner to the outer leaflet of the plasma membrane during apoptosis. Positive staining
with annexin-V correlates with the loss of plasma membrane polarity, but this staining precedes the
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complete loss of membrane integrity that accompanies the later stages of cell death, resulting from
either apoptosis or necrosis. In contrast, PI can only enter cells after complete loss of membrane
integrity. Thus, dual staining for annexin-V and with PI permits discrimination between unaffected
cells (annexin-V−/PI−), early apoptotic cells (annexin-V+/PI−), late apoptotic cells (annexin-V+/PI+),
and necrotic cells (annexin-V−/PI+). The results obtained are shown in Figure 3.
Figure 3. Effects of the tetrahydrothieno[2,3-c]pyridines 3a and 3b on apoptosis. K562 cells were treated
with compounds 3a (A–D) and 3b (E–H), and apoptosis was analyzed by cytofluometry. Analyses
were performed after 3 days of cell culture at the indicated concentrations of 3a and 3b compounds. In
panels A–C and E–G, representative analyses of apoptosis are reported for compound 3a (A–C) and
compound 3b (E–G). In panels D and H, a summary of three independent experiments is presented.
The data represent the average ± S.D. **: highly significant (p < 0.01).
The obtained two parameter histograms demonstrate the effects of different concentrations of 3a
(IC50: 0.75 µM and IC75: 1.00 µM) and 3b (IC50: 0.70 µM and IC75: 0.90 µM) on K562 cells after 72 h of
treatment. Both compounds induced an accumulation of annexin-V positive cells in comparison with
the control, and this accumulation was dose dependent. In the representative experiment shown in
Figure 3, the amount of total apoptotic cells did not exceed 11% in the negative controls (not treated
samples). On the contrary, compound 3b at the IC50 (0.70 µM) and IC75 (0.90 µM) values after 72
h of treatment showed 32.87% and 56.01% cells undergoing apoptosis, respectively. Similarly, 3a is
also very effective in the induction of apoptosis in a dose-dependent manner, showing 29.64% and
46.68% cells in apoptotic phase at its IC50 (0.75 µM) and IC75 (1.00 µM) values, respectively. The results
indicated that most of K562 cells treated with 3a and 3b undergo apoptosis.
3.5. Molecular Modeling Studies
The potential interaction between compounds 3a and 3b and the colchicine site was investigated
through molecular docking studies, using Glide. [54] The colchicine-tubulin complex (PDB ID: 4O2B)
crystal structure was selected as the protein for the docking simulation. [55]
Both compounds seem to occupy the binding site partially overlapping the co-crystallized
colchicine, with the trimethoxyphenyl ring orientated towards the nearby α-tubulin subunit, with
interactions αSer178 and αThr179 (Figure 4A,B). The N-methoxy/ethoxycarbonyl moiety at the
6-position of the tetrahydrothieno[2,3-c]pyridine ring is placed in proximity and interacts with either
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the polypeptide backbone of β-tubulin or with the sidechain of βCys241, a key interaction point for
tubulin polymerization inhibition. Interestingly, the two molecules adopt a different orientation than
the canonical binding previously reported for several tubulin inhibitors, including combretastatin A-4,
in which the trimethoxyphenyl ring is placed in the β-tubulin subunit in proximity to βCys241 [56,57].
This occupation of the colchicine site seems to be fundamental for strong inhibition of tubulin
polymerization, and therefore, the different orientation found for compounds 3a and 3b could explain
their apparently weaker binding to tubulin and causing their reduced inhibitory effects on tubulin
assembly/colchicine binding described above.
Figure 4. Proposed binding modes for compounds 3a (A) and 3b (B) in the colchicine site. The
trimethoxyphenyl ring is oriented towards the α-tubulin subunit, while the N-methoxy/ethoxycarbonyl
moiety at the 6-position of the tetrahydrothieno[2,3-c]pyridine ring is placed in proximity of βCys241.
Co-crystallized colchicine is shown in orange. The tubulin α subunit is shown as a dark green ribbon,
while the β subunit is represented as a cornflower blue ribbon.
4. Materials and Methods
4.1. Chemistry
4.1.1. Materials and Methods
1H experiments were recorded on either a Bruker AC 200 or a Varian 400 Mercury Plus spectrometer,
while 13C-NMR spectra were recorded on a Varian 400 Mercury Plus spectrometer. Chemical shifts (δ)
are given in ppm upfield, and the spectra were recorded in appropriate deuterated solvents, as indicated.
Positive-ion electrospray ionization (ESI) mass spectra were recorded on a double-focusing Finnigan
MAT 95 instrument with BE geometry. Melting points (mp) were determined on a Büchi-Tottoli
apparatus and are uncorrected. All products reported showed 1H and 13C-NMR spectra in agreement
with the assigned structures. The purity of tested compounds was determined by combustion elemental
analyses conducted by the Microanalytical Laboratory of the Chemistry Department of the University
of Ferrara with a Yanagimoto MT-5 CHN recorder elemental analyzer. All tested compounds yielded
data consistent with a purity of at least 95% as compared with the theoretical values. All reactions
were carried out under an inert atmosphere of dry nitrogen, unless otherwise indicated. Standard
syringe techniques were used for transferring dry solvents. Reaction courses and product mixtures
were routinely monitored by Thin Layer Chromatography (TLC) on silica gel (precoated F254 Merck
plates), and compounds were visualized with aqueous KMnO4. Flash chromatography was performed
using 230–400 mesh silica gel and the indicated solvent system. Organic solutions were dried over
anhydrous Na2SO4.
4.1.2. General Procedure A for the Synthesis of Compounds (4a–4p)
To a suspension of malonitrile or cyanoacetate (methyl/ethyl/t-butylcyanoacetate) (5 mmol),
the appropriate ketone corresponding to 4-methyl/phenylcyclohexanone, N-acetyl-4-piperidone or
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methoxy/ethoxycarbonyl-4-piperidone (5 mmol), TEA (0.44 mL, 5 mmol) and sulfur (164 mg, 5 mmol)
in the appropriate solvent (methanol or ethanol, 10 mL) was stirred for 2 h at 70 ◦C. The solvent was
evaporated, and the residue was diluted with dichloromethane (15 mL). After washing with water
(2 × 5 mL) and brine (5 mL), the organic layer was dried over anhydrous Na2SO4 and evaporated.
The crude product was purified by column chromatography on silica gel or by crystallization from
ethyl ether.
Methyl 2-amino-3-cyano-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate (4a). Following general
procedure A, the crude residue obtained by the condensation between malononitrile and methyl
4-oxopiperidine-1-carboxylate in ethanol as solvent was purified by crystallization with ethyl ether to
furnish 4a as an orange solid. Yield: 87%, m.p. 131–133 ◦C. 1H-NMR (d6-DMSO) δ: 2.38–2.44 (m, 2H),
3.56–3.59 (m, 2H), 3.62 (s, 3H), 4.29 (s, 2H), 7.14 (bs, 2H). MS (ESI): [M + 1]+ = 238.3.
Ethyl 2-amino-3-cyano-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate (4b). Following general
procedure A, the crude residue obtained by the condensation between malononitrile and ethyl
4-oxopiperidine-1-carboxylate in ethanol as solvent was purified by crystallization with ethyl ether to
furnish 4b as an orange solid. Yield: 87%, m.p. 171–174 ◦C. 1H–NMR (CDCl3) δ: 1.29 (t, J = 7.2 Hz,
3H), 2.77 (t, J = 5.8 Hz, 2H), 3.74 (t, J = 5.8 Hz, 2H), 4.21 (q, J = 7.2 Hz, 2H), 4.56 (s, 2H), 4.67 (bs, 2H).
MS (ESI): [M + 1]+ = 252.3.
Dimethyl 2–amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (4c). Following general procedure
A, the crude residue obtained by the condensation between methyl 2-cyanoacetate and methyl
4-oxopiperidine-1-carboxylate in methanol as solvent was purified by crystallization with ethyl ether
to furnish 4c as a brown solid. Yield: 67%, m.p. 135–137 ◦C. 1H-NMR (CDCl3) δ: 2.80–2.82 (m, 2H),
3.66 (t, J = 6.0 Hz, 2H), 3.74 (s, 3H), 3.86 (s, 3H), 4.42 (s, 2H), 4.52 (bs, 2H). MS (ESI): [M + 1]+ = 271.3.
6-Ethyl 3-methyl 2-amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (4d). Following general
procedure A, the crude residue obtained by the condensation between methyl 2-cyanoacetate and ethyl
4-oxopiperidine-1-carboxylate in methanol as solvent was purified by crystallization with ethyl ether
to furnish 4d as a yellow solid. Yield: 84%, m.p. 152–154 ◦C. 1H-NMR (CDCl3) δ: 1.27 (t, J = 7.0 Hz,
3H), 2.81 (t, J = 6.0 Hz, 2H), 3.66 (t, J = 6.0 Hz, 2H), 3.90 (s, 3H), 4.11 (bs, 2H), 4.15 (q, J = 7.0 Hz, 2H),
4.42 (s, 2H). MS (ESI): [M + 1]+ = 285.4.
Methyl 6-acetyl-2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (4e). Following general
procedure A, the crude residue obtained by the condensation between methyl 2-cyanoacetate and
1-acetylpiperidin-4-one in methanol as solvent was purified by crystallization with ethyl ether to
furnish 4e as a yellow solid. Yield: 72%, m.p. 144–146 ◦C. 1H-NMR (CDCl3) δ: 2.24 (s, 3H), 2.87 (t,
J = 6.0 Hz, 2H), 3.72 (t, J = 6.0 Hz, 2H), 3.80 (s, 3H), 4.51 (s, 2H), 5.14 (bs, 2H). MS (ESI): [M + 1]+ = 255.3.
3-Ethyl 6-methyl 2-amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (4f). Following general
procedure A, the crude residue obtained by the condensation between ethyl 2-cyanoacetate and methyl
4-oxopiperidine-1-carboxylate in ethanol as solvent was purified by crystallization with ethyl ether to
furnish 4f as a yellow solid. Yield: 64%, m.p. 151–153 ◦C. 1H-NMR (CDCl3) δ: 1.33 (t, J = 7.0 Hz, 3H),
2.80-2.82 (m, 2H), 3.66 (t, J = 6.0 Hz, 2H), 3.74 (s, 3H), 3.78 (bs, 2H), 4.24 (q, J = 7.0 Hz, 2H), 4.41 (s, 2H).
MS (ESI): [M + 1]+ = 285.4.
Diethyl 2-amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (4g). Following general procedure
A, the crude residue obtained by the condensation between ethyl 2-cyanoacetate and ethyl
4-oxopiperidine-1-carboxylate in ethanol as solvent was purified by crystallization with ethyl ether to
furnish 4g as a yellow solid. Yield: 78%, m.p. 145–147 ◦C. 1H-NMR (d6-DMSO) δ: 1.15-1.28 (m, 6H),
2.64-2.67 (m, 2H), 3.55 (t, J = 6.0 Hz, 2H), 4.04 (q, J = 7.2 Hz, 2H), 4.16 (q, J = 7.2 Hz, 2H), 4.29 (s, 2H),
7.32 (bs, 2H). MS (ESI): [M + 1]+ = 299.1.
Ethyl 6-acetyl-2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (4h). Following general
procedure (A), the crude residue obtained by the condensation between ethyl 2-cyanoacetate and
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1-acetylpiperidin-4-one in ethanol as solvent was purified by crystallization with ethyl ether to furnish
4h as a yellow solid. Yield: 69%, m.p. 135–137 ◦C. 1H-NMR (CDCl3) δ: 1.36 (t, J = 7.4 Hz, 3H), 2.26 (s,
3H), 2.89 (t, J = 6.0 Hz, 2H), 3.73 (t, J = 6.0 Hz, 2H), 4.29 (q, J = 7.2 Hz, 2H), 4.38 (s, 2H), 4.96 (bs, 2H).
MS (ESI): [M + 1]+ = 269.3.
3-tert-butyl 6-methyl 2-amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (4i). Following general
procedure A, the crude residue obtained by the condensation between methyl 2-cyanoacetate and
tert-butyl 4-oxopiperidine-1-carboxylate in methanol as solvent was purified by crystallization with
ethyl ether to furnish 4i as a yellow solid. Yield: 78%, m.p. 134–136 ◦C. 1H-NMR (CDCl3) δ: 1.57 (s, 9H),
2.76–2.81 (m, 2H), 3.66–3.70 (m, 2H), 3.73 (s, 3H), 4.45 (s, 2H), 4.54 (bs, 2H). MS (ESI): [M + 1]+ = 313.4.
3-tert-butyl 6-ethyl 2-amino-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (4j). Following general
procedure A, the crude residue obtained by the condensation between ethyl 2-cyanoacetate and
tert-butyl 4-oxopiperidine-1-carboxylate in ethanol as solvent was purified by crystallization with ethyl
ether to furnish 4j as a yellow solid. Yield: 84%, m.p. 152–154 ◦C. 1H-NMR (CDCl3) δ: 1.29 (t, J = 7.2
Hz, 3H), 1.55 (s, 9H), 2.78–2.81 (m, 2H), 3.66-3.69 (m, 2H), 4.19 (q, J = 7.2 Hz, 2H), 4.46 (s, 2H), 4.84 (bs,
2H). MS (ESI): [M + 1]+ = 327.4.
2. -Amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (4k). Following general procedure
A, the crude residue obtained by the condensation between malononitrile and 4-methylcyclohexanone
in methanol as solvent was purified by trituration of the crude product with ethyl ether to furnish 4k as
a yellow solid. Yield: 58%, m.p. 124–126 ◦C. 1H-NMR (CDCl3) δ: 1.03 (d, J = 6.6 Hz, 3H), 1.39–1.42 (m,
1H), 1.84–1.88 (m, 2H), 2.08–2.12 (m, 1H), 2.56–2.60 (m, 3H), 4.29 (bs, 2H). MS (ESI): [M + 1]+ = 193.3.
2. -Amino-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (4l). Following general procedure
(A), the crude residue obtained by the condensation between malononitrile and 4-phenylcyclohexanone
in ethanol as solvent was purified by trituration of the crude product with ethyl ether to furnish 4l
as a yellow solid. Yield: 71%, m.p. 180–182 ◦C. 1H-NMR (CDCl3) δ: 1.19–1.22 (m, 1H), 2.07–2.10
(m, 1H), 2.66–2.71 (m, 3H), 2.72–2.76 (m, 2H), 2.97–3.00 (m, 1H), 3.39 (bs, 2H), 7.32 (m, 5H). MS (ESI):
[M + 1]+ = 255.2.
Methyl 2-amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (4m). Following general
procedure A, the crude residue obtained by the condensation between methyl 2-cyanoacetate and
4-methylcyclohexanone in methanol as solvent was purified by flash chromatography on silica gel,
using ethyl acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 4m as a yellow solid. Yield: 65%, m.p.
109–110 ◦C. 1H-NMR (CDCl3) δ: 1.03 (d, J = 6.2 Hz, 3H), 1.34–1.38 (m, 1H), 1.84–1.88 (m, 2H), 2.15–2.19
(m, 1H), 2.63–2.66 (m, 2H), 2.84–2.87 (m, 1H), 3.88 (s, 3H), 4.64 (bs, 2H). MS (ESI): [M + 1]+ = 226.3.
Methyl 2-amino-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (4n). Following general
procedure A, the crude residue obtained by the condensation between methyl 2-cyanoacetate and
4-phenylcyclohexanone in methanol as solvent was purified by flash chromatography on silica gel,
using ethyl acetate:petroleum ether 4:6 (v:v) as eluent, to furnish 4n as a white solid. Yield: 62%, m.p.
132–134. ◦C 1H-NMR (CDCl3) δ: 1.80–1.84 (m, 1H), 2.02–2.06 (m, 1H), 2.75–2.79 (m, 3H), 2.99–3.02 (m,
2H), 3.86 (s, 3H), 4.82 (bs, 2H), 7.23–7.36 (m, 5H). MS (ESI): [M + 1]+ = 288.2.
Ethyl 2-amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (4o). Following general
procedure A, the crude residue obtained by the condensation between ethyl 2-cyanoacetate and
4-methylcyclohexanone in ethanol as solvent was purified by flash chromatography on silica gel, using
ethyl acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 4o as a yellow solid. Yield: 63%, m.p.
112–114. ◦C 1H-NMR (CDCl3) δ: 1.03 (d, J = 6.2 Hz, 3H), 1.29–1.32 (m, 1H), 1.35 (t, J = 7.0 Hz, 3H),
1.84–1.87 (m, 2H), 2.14–2.17 (m, 1H), 2.63–2.68 (m, 2H), 2.84–2.88 (m, 1H), 4.32 (q, J = 7.0 Hz, 2H), 5.82
(bs, 2H). MS (ESI): [M + 1]+ = 240.3.
Ethyl 2-amino-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (4p). Following general
procedure A, the crude residue obtained by the condensation between ethyl 2-cyanoacetate and
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4-phenylcyclohexanone in ethanol as solvent was purified by flash chromatography on silica gel, using
ethyl acetate:petroleum ether 4:6 (v:v) as eluent, to furnish 4p as a yellow oil. Yield: 59%. 1H-NMR
(CDCl3) δ: 1.34 (t, J = 7.0 Hz, 3H), 1.90–1.95 (m, 1H), 2.10–2.14 (m, 1H), 2.77–2.82 (m, 3H), 3.02–3.06 (m,
2H), 4.34 (q, J = 7.0 Hz, 2H), 4.76 (bs, 2H), 7.24–7.33 (m, 5H). MS (ESI): [M + 1]+ = 302.3.
4.1.3. General Procedure B for the Synthesis of Compounds (5a–p)
In a dry three-necked round-bottom flask, anhydrous CuBr2 (536 mg, 2.4 mmol) and tert-butyl
nitrite (360 µL, 3 mmol) were dissolved in anhydrous acetonitrile (10 mL) under an argon atmosphere.
The resulting mixture was warmed at 65 ◦C and 2-amino derivative 4a–p (2 mmol) in acetonitrile (5
mL) was slowly added. The reaction was complete after 2 h, as monitored by TLC. The dark mixture
was allowed to reach room temperature, poured in a saturated aqueous NH4Cl solution (10 mL), and
extracted with CH2Cl2 (30 mL). The organic phase was washed twice with a saturated aqueous NH4Cl
solution (10 mL) and brine (10 mL), dried over Na2SO4, and concentrated at reduced pressure to
furnish a residue that was purified by flash chromatography on silica gel.
Methyl 2-bromo-3-cyano-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate (5a). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 3:7 (v:v) as eluent, to furnish 5a as a yellow solid. Yield: 64%, m.p. 153–155 ◦C. 1H-NMR (CDCl3)
δ: 2.77 (t, J = 5.8 Hz, 2H), 3.71 (t, J = 5.8 Hz, 2H), 3.75 (s, 3H), 4.56 (s, 2H). MS (ESI): [M] + = 301.2,
[M + 2]+ = 303.2.
Ethyl 2-bromo-3-cyano-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate (5b). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 3:7 (v:v) as eluent, to furnish 5b as a white solid. Yield: 64%, m.p. 171–173 ◦C. 1H-NMR (CDCl3)
δ: 1.28 (t, J = 7.0 Hz, 3H), 2.81 (t, J = 5.8 Hz, 2H), 3.73 (t, J = 5.8 Hz, 2H), 4.17 (q, J = 7.0 Hz, 2H), 4.66 (s,
2H). MS (ESI): [M]+ = 315.2, [M + 2]+ = 317.2.
Dimethyl 2-bromo-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (5c). Following general procedure
B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 3:7
(v:v) as eluent, to furnish 5c as a colorless oil. Yield: 64%. 1H-NMR (CDCl3) δ: 2.89 (t, J = 5.8 Hz, 2H),
3.68 (t, J = 5.8 Hz, 2H), 3.73 (s, 3H), 3.83 (s, 3H), 4.54 (s, 2H). MS (ESI): [M]+ = 334.1, [M + 2]+ = 336.3.
6-Ethyl 3-methyl 2-bromo-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (5d). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 2:8 (v:v) as eluent, to furnish 5d as a yellow oil. Yield: 73%. 1H-NMR (CDCl3) δ: 1.28 (t, J = 7.2
Hz, 3H), 2.89 (t, J = 6.0 Hz, 2H), 3.68 (t, J = 5.8 Hz, 2H), 3.87 (s, 3H), 4.16 (q, J = 7.2 Hz, 2H), 4.54 (s, 2H).
MS (ESI): [M]+ = 348.3, [M + 2]+ = 350.3.
Methyl 6-acetyl-2-bromo-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (5e). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 1:9 (v:v) as eluent, to furnish 5e as a brown oil. Yield: 68%. 1H-NMR (CDCl3) δ: 2.21 (s, 3H), 3.05 (t,
J = 6.0 Hz, 2H), 3.68 (t, J = 5.8 Hz, 2H), 3.83 (s, 3H), 4.76 (s, 2H). MS (ESI): [M]+ = 318.3, [M + 2]+ = 320.3.
3-Ethyl 6-methyl 2-bromo-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (5f). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 2:8 (v:v) as eluent, to furnish 5f as a yellow solid. Yield: 65%, m.p. 110–112 ◦C. 1H-NMR (CDCl3)
δ: 1.32 (t, J = 7.2 Hz, 3H), 2.90 (t, J = 6.0 Hz, 2H), 3.68 (t, J = 5.8 Hz, 2H), 3.74 (s, 3H), 4.29 (q, J = 7.2 Hz,
2H), 4.55 (s, 2H). MS (ESI): [M]+ = 348.3, [M + 2]+ = 350.3.
Diethyl 2-bromo-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (5g). Following general procedure
B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 2:8
(v:v) as eluent, to furnish 5g as a yellow oil. Yield: 58%. 1H-NMR (CDCl3) δ: 1.28 (t, J = 7.0 Hz, 3H),
1.35 (t, J = 7.0 Hz, 3H), 2.86 (t, J = 5.6 Hz, 2H), 3.68 (t, J = 5.8 Hz, 2H), 4.16 (q, J = 7.2 Hz, 2H), 4.34 (q,
J = 7.2 Hz, 2H), 4.54 (s, 2H). MS (ESI): [M]+ = 362.1, [M + 2]+ = 364.3.
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Ethyl 6-acetyl-2-bromo-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (5h). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 1:9 (v:v) as eluent, to furnish 5h as a brown oil. Yield: 69%. 1H-NMR (CDCl3) δ: 1.35 (t, J = 7.2
Hz, 3H), 2.22 (s, 3H), 3.05 (t, J = 6.0 Hz, 2H), 3.72 (t, J = 5.8 Hz, 2H), 4,27 (q, J = 7.2 Hz, 2H), 4.76 (s, 2H).
MS (ESI): [M]+ = 332.3, [M + 2]+ = 334.3.
3-tert-butyl 6-methyl 2-bromo-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (5i). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 2:8 (v:v) as eluent, to furnish 5i as a colorless oil. Yield: 63%. 1H-NMR (CDCl3) δ: 1.57 (s, 9H),
2.87 (t, J = 6.0 Hz, 2H), 3.67 (t, J = 5.8 Hz, 2H), 3.74 (s, 3H), 4.54 (s, 2H). MS (ESI): [M]+ = 376.3,
[M + 2]+ = 378.3.
3-tert-butyl 6-ethyl 2-bromo-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (5j). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 2:8 (v:v) as eluent, to furnish 5j as a colorless oil. Yield: 71%. 1H-NMR (CDCl3) δ: 1.26 (t, J = 7.2
Hz, 3H), 1.55 (s, 9H), 2.87 (t, J = 6.0 Hz, 2H), 3.71 (t, J = 5.8 Hz, 2H), 4.16 (q, J = 7.2 Hz, 2H), 4.53 (s, 2H).
MS (ESI): [M]+ = 390.3, [M + 2]+ = 392.3.
2. -Bromo-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (5k). Following general procedure B,
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 0.5:9.5
(v:v) as eluent, to furnish 5k as a green oil. Yield: 72%. 1H-NMR (CDCl3) δ: 1.06 (d, J = 6.2 Hz, 3H),
1.26–1.28 (m, 1H), 1.89–1.92 (m, 2H), 2.20–2.24 (m, 1H), 2.69–2.72 (m, 3H). MS (ESI): [M]+ = 256.2,
[M + 2]+ = 258.2.
2. -Bromo-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (5l). Following general procedure B,
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum ether 0.5:9.5 (v:v)
as eluent, to furnish 5l as a brown oil. Yield: 63%. 1H-NMR (CDCl3) δ: 1.80–1.83 (m, 1H), 2.17–2.20 (m,
1H), 2.75–2.79 (m, 3H), 2.98–3.01 (m, 2H), 7.26–7.31 (m, 5H). MS (ESI): [M]+ = 318.2, [M + 2]+ = 320.3.
Methyl 2-bromo-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5m). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 0.5:9.5 (v:v) as eluent, to furnish 5m as a colorless oil. Yield: 63%. 1H-NMR (CDCl3) δ: 1.06 (d,
J = 6.6 Hz, 3H), 1.30–1.32 (m, 1H), 1.89-1.92 (m, 2H), 2.24–2.28 (m, 1H), 2.74-2.78 (m, 2H), 3.03-3.06 (m,
1H), 3.84 (s, 3H). MS (ESI): [M]+ = 289.2, [M + 2]+ = 291.2.
Methyl 2-bromo-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5n). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 0.5:9.5 (v:v) as eluent, to furnish 5n as a colorless oil. Yield: 70%. 1H-NMR (CDCl3) δ: 1.77–1.82
(m, 1H), 2.08–2.10 (m, 1H), 2.78–2.82 (m, 3H), 3.00–3.04 (m, 2H), 3.84 (s, 3H), 7.24–7.30 (m, 5H). MS
(ESI): [M]+ = 351.3, [M + 2]+ = 353.4.
Ethyl 2-bromo-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5o). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 0.5:9.5 (v:v) as eluent, to furnish 5o as a colorless oil. Yield: 72%. 1H-NMR (CDCl3) δ: 1.07 (d,
J = 6.6 Hz, 3H), 1.31–1.34 (m, 1H), 1.37 (t, J = 7.0 Hz, 3H), 1.78-1.82 (m, 2H), 2.17–2.21 (m, 1H), 2.68–2.75
(m, 2H), 2.86–2.88 (m, 1H), 4.26 (q, J = 7.0 Hz, 2H). MS (ESI): [M]+ = 303.2, [M + 2]+ = 305.2.
Ethyl 2-bromo-6-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5p). Following general
procedure B, the crude residue was purified by flash chromatography, using ethyl acetate:petroleum
ether 0.5:9.5 (v:v) as eluent, to furnish 5p as a colorless oil. Yield: 68%. 1H-NMR (CDCl3) δ: 1.36 (t,
J = 7.0 Hz, 3H), 1.78–1.82 (m, 1H), 2.00–2.05 (m, 1H), 2.76–2.80 (m, 3H), 2.97–3.02 (m, 2H), 4.33 (q, J = 7.0
Hz, 2H), 7.24–7.33 (m, 5H). MS (ESI): [M]+ = 365.4, [M + 2]+ = 367.4.
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4.1.4. General Procedure C for the Preparation of Compounds (3a–3p)
A dry Schlenk tube was charged with dry toluene (5 mL), 2-bromo derivative 3a–p (0.5 mmol),
Pd(OAc)2 (3 mol%, 15 mg), rac-BINAP (4 mol%, 15 mg), Cs2CO3 (230 mg, 0.7 mmol, 1.4 equiv.), and
3,4,5-trimethoxyaniline (137 mg, 0.75 mmol, 1.5 equiv.) under argon, and the mixture was heated at
100 ◦C for 18 h. After cooling, the mixture was filtered on a pad of celite and the filtrate diluted with
EtOAc (10 mL) and water (5 mL). The organic phase was washed with brine (5 mL), dried over Na2SO4,
and concentrated under vacuum. The residue was purified by column chromatography on silica gel.
Methyl 3-cyano-2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate (3a).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3a as a yellow solid. Yield: 58%, m.p. 180–181 ◦C.
1H-NMR (d6-DMSO) δ: 2.50–2.53 (m, 2H), 3.59 (s, 3H), 3.62 (t, J = 5.8 Hz, 2H), 3.69 (s, 3H), 3.72 (s,
6H), 4.39 (s, 2H), 6.53 (s, 2H), 9.55 (s, 1H). 13C-NMR (d6-DMSO) δ: 23.92, 30.58, 42.31, 52.54, 55.66 (2C),
60.02, 90.03, 95.76 (2C), 114.79, 117.84, 130.87, 132.83, 137.99, 153.22 (2C), 155.41, 157.49. MS (ESI):
[M + 1]+ = 404.3. Anal. calcd for C19H21N3O5S: C, 56.56; H, 5.25; N, 10.42; found: 56.38; H, 5.11; N,
10.21.
Ethyl 3-cyano-2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate (3b).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 4:6 (v:v) as eluent, to furnish 3b as a yellow solid. Yield: 51%, m.p. 134–136 ◦C.
1H-NMR (d6-DMSO) δ: 1.15 (t, J = 7.2 Hz, 3H), 2.50-2.53 (m, 2H), 3.59 (s, 3H), 3.63 (t, J = 5.8 Hz, 2H),
3.72 (s, 6H), 4.05 (q, J = 7.2 Hz, 2H), 4.39 (s, 2H), 6.53 (s, 2H), 9.55 (s, 1H). 13C-NMR (d6-DMSO) δ:
14.46, 23.92, 42.22, 55.67 (2C), 60.02, 61.02, 61.18, 95.74 (2C), 105.76, 114.80, 117.35, 130.89, 132.82, 137.99,
153.22 (2C), 154.62, 157.47. MS (ESI): [M + 1]+ = 418.4. Anal. calcd for C20H23N3O5S: C, 57.54; H, 5.55;
N, 10.07; found: C, 57.32; H, 5.38; N, 9.98.
Dimethyl 2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (3c).
Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 4:6 (v:v) as eluent, to furnish 3c as a white solid. Yield: 58%, m.p.
140–141 ◦C. 1H-NMR (d6-DMSO) δ: 2.75 (t, J = 5.6 Hz, 2H), 3.59 (t, J = 5.6 Hz, 2H), 3.63 (s, 6H), 3.78 (s,
9H), 4.39 (s, 2H), 6.68 (s, 2H), 9.62 (s, 1H). 13C-NMR (d6-DMSO) δ: 14.52, 26.24, 42.82, 51.51, 56.38 (2C),
60.20, 60.57, 97.92 (2C), 105.92, 114.33, 131.23, 134.09, 137.31, 153.86 (2C), 155.65, 158.70, 165.79. MS
(ESI): [M + 1]+ = 437.5. Anal. calcd for C20H24N2O7S: C, 55.03; H, 5.54; N, 6.42; found: C, 54.89; H,
5.23; N, 6.30.
6-Ethyl 3-methyl 2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate
(3d). Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 4:6 (v:v) as eluent, to furnish 3d as a yellow solid. Yield: 55%, m.p.
76–78 ◦C. 1H-NMR (d6-DMSO) δ: 1.19 (t, J = 6.8 Hz, 3H), 2.82 (t, J = 5.8 Hz, 2H), 3.62 (t, J = 5.8 Hz,
2H), 3.64 (s, 3H), 3.77 (s, 3H), 3.78 (s, 6H), 4.06 (q, J = 6.8 Hz, 2H), 4.39 (s, 2H), 6.68 (s, 2H), 9.64 (s,
1H). 13C-NMR (d6-DMSO) δ: 14.58, 26.51, 42.30, 51.08, 55.94 (2C), 59.77, 60.14, 61.00, 97.43 (2C), 105.48,
114.32, 130.80, 133.64, 136.87, 153.42 (2C), 155.02, 158.24, 165.37. MS (ESI): [M + 1]+ = 451.5. Anal.
(C21H26N2O7S) C, H, N. Anal. calcd for C21H26N2O7S. C, 55.99; H, 5.82; N, 6.22; found: C, 55.78; H,
5.64; N, 6.10.
Methyl 6-acetyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (3e).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 1:9 (v:v) as eluent, to furnish 3e as a yellow solid. Yield: 54%, m.p. 90–91 ◦C.
1H-NMR (d6-DMSO) δ: 2.06 (s, 3H), 2.79-2.82 (m, 2H), 3.61-3.64 (m, 5H), 3.76 (s, 9H), 4.42 (s, 2H), 6.66
(s, 2H), 9.61 (s, 1H). 13C-NMR (d6-DMSO) δ: 20.98, 27.09, 42.94, 43.98, 50.97, 55.83 (2C), 60.02, 97.31 (2C),
105.38, 114.08, 130.65, 133.52, 136.76, 153.31 (2C), 158.02, 165.22, 168.33. MS (ESI): [M + 1]+ = 421.3.
Anal. calcd for C20H24N2O6S: C, 57.13; H, 5.75; N, 6.66; found: 57.01; H, 5.58; N, 6.48.
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3-Ethyl 6-methyl 2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate
(3f). Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3f as a yellow solid. Yield: 59%, m.p.
128–130 ◦C. 1H-NMR (d6-DMSO) δ: 1.27 (t, J = 7.2 Hz, 3H), 2.73-2.75 (m, 2H), 3.52-3.54 (m, 2H), 3.58 (s,
6H), 3.79 (s, 6H), 4.21 (q, J = 7.2 Hz, 2H), 4.40 (s, 2H), 6.65 (s, 2H), 9.69 (s, 1H). 13C-NMR (d6-DMSO) δ:
14.21, 26.63, 42.41, 52.57, 55.09, 55.94 (2C), 59.72, 60.13, 97.17 (2C), 105.63, 114.55, 130.71, 133.53, 136.82,
153.44 (2C), 155.12, 158.07, 165.10. MS (ESI): [M + 1]+ = 451.6. Anal. calcd for C21H26N2O7S: C, 55.99;
H, 5.82; N, 6.22; found: 55.77; H, 5.63; N, 6.02.
Diethyl 2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate (3g).
Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3g as a yellow solid. Yield: 63%, m.p.
67–69 ◦C. 1H-NMR (d6-DMSO) δ: 1.18 (t, J = 7.2 Hz, 3H), 1.29 (t, J = 7.2 Hz, 3H), 2.77 (t, J = 5.6 Hz, 2H),
3.62 (t, J = 5.6 Hz, 2H), 3.64 (s, 3H), 3.78 (s, 6H), 4.06 (q, J = 7.2 Hz, 2H), 4.23 (q, J = 7.2 Hz, 2H), 4.39 (s,
2H), 6.67 (s, 2H), 9.73 (s, 1H). 13C-NMR (d6-DMSO) δ: 14.20, 14.58, 26.33, 30.69, 42.31, 55.94, 59.72 (2C),
60.13, 61.00, 97.13 (2C), 105.62, 114.29, 130.74, 133.53, 136.81, 153.44 (2C), 154.67, 158.06, 165.12. MS
(ESI): [M + 1]+ = 465.6. Anal. (C22H28N2O7S) C, H, N. Anal. calcd for C22H28N2O7S: C, 56.88; H, 6.08;
N, 6.03; found: C, 56.65; H, 5.92; N, 5.88.
Ethyl 6-acetyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (3h).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 1:9 (v:v) as eluent, to furnish 3h as a white solid. Yield: 54%, m.p. 93-95 ◦C.
1H-NMR (d6-DMSO) δ: 1.28 (t, J = 7.2 Hz, 3H), 2.09 (s, 3H), 2.78-2.80 (m, 2H), 3.63 (s, 3H), 3.64-3.66 (m,
2H), 3.78 (s, 6H), 4.26 (q, J = 7.2 Hz, 2H), 4.45 (s, 2H), 6.67 (s, 2H), 9.72 (s, 1H). 13C-NMR (d6-DMSO) δ:
14.14, 20.99, 27.14, 42.97, 44.05, 55.83 (2C), 59.60, 60.02, 97.08 (2C), 105.54, 114.56, 130.59, 133.41, 136.71,
153.33 (2C), 157.97, 164.99, 168.33. MS (ESI): [M + 1]+ = 435.4. Anal. calcd for C21H26N2O6S: C, 62.20;
H, 6.71; N, 3.45; found: C, 62.04; H, 6.58; N, 3.23.
3-tert-butyl 6-methyl 2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate
(3i). Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3i as a white solid. Yield: 64%, m.p.
50–52 ◦C. 1H-NMR (d6-DMSO) δ: 1.53 (s, 9H), 2.72–2.75 (m, 2H), 3.59 (t, J = 5.8 Hz, 2H), 3.63 (s, 3H),
3.76 (s, 3H), 3.78 (s, 6H), 4.40 (s, 2H), 6.67 (s, 2H), 9.74 (s, 1H). 13C-NMR (d6-DMSO) δ: 26.78, 27.98 (3C),
42.35, 52.47, 55.86 (2C), 59.67, 60.05, 80.50, 96.83 (2C), 106.89, 113.97, 130.67, 133.32, 136.74, 153.35 (2C),
155.02, 157.42, 164.75. MS (ESI): [M + 1]+ = 479.5. Anal. calcd for C23H30N2O7S: C, 57.72; H, 6.32; N,
5.85; found: C, 57.54; H, 6.21; N, 5.67.
3-tert-butyl 6-ethyl 2-((3,4,5-trimethoxyphenyl)amino)-4,5-dihydrothieno[2,3-c]pyridine-3,6(7H)-dicarboxylate
(3j). Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3j as a yellow solid. Yield: 70%, m.p.
60–62 ◦C. 1H-NMR (d6-DMSO) δ: 1.17 (t, J = 7.2 Hz, 3H), 1.53 (s, 9H), 2.74 (t, J = 5.8 Hz, 2H), 3.59 (t,
J = 5.8 Hz, 2H), 3.63 (s, 3H), 3.78 (s, 6H), 4.06 (q, J = 7.2 Hz, 2H), 4.39 (s, 2H), 6.67 (s, 2H), 9.75 (s, 1H).
13C-NMR (d6-DMSO) δ: 15.04, 24.02, 28.50 (3C), 31.14, 42.77, 56.38 (2C), 60.57, 61.44, 81.03, 97.32 (2C),
107.39, 114.04, 131.42, 133.83, 137.26, 153.88 (2C), 155.31, 157.93, 165.30. MS (ESI): [M + 1]+ = 493.4.
Anal. calcd for C24H32N2O7S: C, 58.52; H, 6.55; N, 5.69; found: C, 58.29; H, 6.29; N, 5.41.
6. -Methyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (3k).
Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3k as a white solid. Yield: 58%, m.p.
112–114 ◦C. 1H-NMR (d6-DMSO) δ: 1.01 (d, J = 6.4 Hz, 3H), 1.37–1.40 (m, 1H), 1.80–1.82 (m, 2H),
2.14–2.18 (m, 1H), 2.50–2.52 (m, 2H), 2.61–2.65 (m, 1H), 3.61 (s, 3H), 3.73 (s, 6H), 6.52 (s, 2H), 9.41
(s, 1H). 13C-NMR (d6-DMSO) δ: 21.61, 24.14, 29.62, 30.31, 32.19, 56.17 (2C), 60.57, 91.43, 95.78 (2C),
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115.76, 121.73, 132.12, 133.00, 138.88, 153.74 (2C), 156.67. MS (ESI): [M + 1]+ = 359.4. Anal. calcd for
C19H22N2O5S: C, 63.66; H, 6.19; N, 7.82; found: C, 63.47; H, 6.01; N, 7.64.
6. -Phenyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (3l).
Following general procedure C, the crude residue was purified by flash chromatography, using
ethyl acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3l as a yellow solid. Yield: 63%, m.p.
169–170 ◦C. 1H-NMR (d6-DMSO) δ: 1.96–1.99 (m, 2H), 2.60–2.63 (m, 3H), 2.74–2.78 (m, 1H), 2.98–3.01
(m, 1H), 3.61 (s, 3H), 3.74 (s, 6H), 6.54 (s, 2H), 7.20–7.23 (m, 1H), 7.30-7.32 (m, 4H), 9.48 (s, 1H). 13C-NMR
(d6-DMSO) δ: 24.80, 29.43, 32.02, 40.02, 56.19 (2C), 60.58, 91.25, 95.92 (2C), 115.75, 121.70, 126.80, 126.32
(2C), 128.87 (2C), 132.22, 133.10, 138.82, 145.91, 153.75 (2C), 156.99. MS (ESI): [M + 1]+ = 421.5. Anal.
(C24H24N2O5S) C, H, N. Anal. calcd for C24H24N2O5S: C, 68.55; H, 5.75; N, 6.66; found: C, 68.34; H,
5.54; N, 6.26.
Methyl 6-methyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (3m).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3m as a white solid. Yield: 55%, m.p. 127-129 ◦C.
1H-NMR (d6-DMSO) δ: 0.99 (d, J = 6.8 Hz, 3H), 1.26-1.30 (m, 1H), 1.76–1.80 (m, 2H), 2.13–2.16 (m,
1H), 2.50–2.54 (m, 2H), 2.82- 2.84 (m, 1H), 3.63 (s, 3H), 3.76 (s, 3H), 3.77 (s, 6H), 6.65 (s, 2H), 9.70
(s, 1H). 13C-NMR (d6-DMSO) δ: 21.67, 26.50, 29.30, 30.93, 32.36, 51.40, 56.35 (2C), 60.57, 97.35 (2C),
106.39, 117.77, 131.88, 133.74, 137.47, 153.83 (2C), 157.61, 166.18. MS (ESI): [M + 1]+ = 392.3. Anal.
(C20H25NO5S) C, H, N. Anal. calcd for C24H24N2O5S: C, 61.36; H, 6.44; N, 3.58; found: C, 61.18; H,
6.23; N, 3.41.
Methyl 6-phenyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (3n).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3n as a white solid. Yield: 61%, m.p. 147-148 ◦C.
1H-NMR (d6-DMSO) δ: 1.79–1.82 (m, 1H), 1.96–2.00 (m, 1H), 2.68–2.72 (m, 3H), 2.83–2.86 (m, 2H), 3.62
(s, 3H), 3.78 (s, 9H), 6.68 (s, 2H), 7.22 (m, 1H), 7.31 (m, 4H), 9.71 (s, 1H). 13C-NMR (d6-DMSO) δ: 26.59,
29.47, 31.52, 40.02, 50.90, 55.82 (2C), 60.02, 97.00 (2C), 105.75, 117.27, 126.11, 126.73 (2C), 128.26 (2C),
131.49, 133.31, 136.90, 145.63, 153.29 (2C), 157.35, 165.60. MS (ESI): [M + 1]+ = 454.4. Anal. calcd for
C25H27NO5S: C, 66.20; H, 6.00; N, 3.09; found: C, 66.01; H, 5.84; N, 2.92.
Ethyl 6-methyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (3o).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3o as a white solid. Yield: 56%, m.p. 90–92 ◦C.
1H-NMR (d6-DMSO) δ: 0.99 (d, J = 6.4 Hz, 3H), 1.26–1.28 (m, 1H), 1.32 (t, J = 7.0 Hz, 3H), 1.79–1.82 (m,
2H), 2.16–2.20 (m, 1H), 2.52–2.58 (m, 2H), 2.79-2.82 (m, 1H), 3.62 (s, 3H), 3.77 (s, 6H), 4.24 (q, J = 7.0
Hz, 2H), 6.64 (s, 2H), 9.79 (s, 1H). 13C-NMR (d6-DMSO) δ: 14.15, 21.10, 26.01, 28.73, 30.43, 31.83, 55.80
(2C), 59.44, 60.02, 96.54 (2C), 105.98, 117.26, 131.29, 133.10, 136.88, 153.31 (2C), 156.89, 165.38. MS (ESI):
[M + 1]+ = 406.3. Anal. calcd for C21H27NO5S: C, 62.20; H, 6.71; N, 3.45; found: C, 62.01; H, 6.48;
N, 3.23.
Ethyl 6-phenyl-2-((3,4,5-trimethoxyphenyl)amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (3p).
Following general procedure C, the crude residue was purified by flash chromatography, using ethyl
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3p as a yellow solid. Yield: 73%, m.p. 98-100 ◦C.
1H-NMR (d6-DMSO) δ: 1.19 (t, J = 6.8 Hz, 3H), 1.84-1.86 (m, 1H), 1.98–2.02 (m, 1H), 2.79–2.84 (m, 3H),
2.97–3.00 (m, 2H), 3.60 (s, 3H), 3.82 (s, 6H), 4.28 (q, J = 7.0 Hz, 2H), 6.67 (s, 2H), 7.19–7.21 (m, 1H),
7.29–7.33 (m, 4H), 9.80 (s, 1H). 13C-NMR (d6-DMSO) δ: 14.17, 26.65, 29.57, 31.49, 55.82 (2C), 59.42, 59.65,
60.02, 96.72 (2C), 105.90, 117.32, 126.13, 126.73 (2C), 128,27 (2C), 131.44, 133.20, 136.86, 145.65, 153.31
(2C), 157.19, 165.35. MS (ESI): [M + 1]+ = 468.4. Anal. calcd for C26H29NO5S: C, 66.79; H, 6.25; N, 3.00;
found: C, 66.58; H, 6.02; N, 2.78.
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4.2. Biological Evaluation
4.2.1. Cell Growth Conditions and Antiproliferative Assay
Murine leukemia L1210, human T-lymphocyte leukemia CEM, human cervix carcinoma (HeLa),
and human chronic myelogenous leukemia K562 cells (3–5 × 104 cells) and a serial (5-fold) dilution
of the test compounds were added to a 96-well microtiter plate. The cells were incubated for 72 h
at 37 ◦C in a humidified 5% CO2 atmosphere. At the end of the incubation period, the cells were
counted in a Coulter Counter (Coulter Electronics Ltd., Harpenden Herts, United Kingdom). The
IC50 (50% inhibitory concentration) was defined as the concentration of compound that inhibited cell
proliferation by 50%. The IC50 values represent the average (± standard deviation) of three independent
experiments. Human peripheral blood mononuclear cells (PBMC) were obtained from healthy donors
by centrifugation with Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB, Uppsala).
4.2.2. Effects on Tubulin Polymerization
Bovine brain tubulin was purified as described previously [58]. To evaluate the effect of the
compounds on tubulin assembly in vitro [59], varying concentrations were preincubated with 10 µM
tubulin in 0.8 M glutamate buffer at 30 ◦C and then cooled to 0 ◦C. After addition of GTP, the
mixtures were transferred to 0 ◦C cuvettes in a recording spectrophotometer and warmed to 30 ◦C,
and the assembly of tubulin was observed turbidimetrically. The IC50 was defined as the compound
concentration that inhibited the extent of assembly by 50% after a 20 min incubation. The ability of the
test compounds to inhibit colchicine binding to tubulin was measured as described earlier [60], except
that the reaction mixtures contained 1 µM tubulin, 5 µM of [3H]colchicine, and test compounds 3a
or 3b.
4.2.3. Effects on the Cell Cycle
Human leukemia K562 cells were treated with compounds 3a or 3b, and analysis of the distribution
of the cells through the cell cycle was performed with the Muse Cell Analyzer instrument (Millipore
Corporation, Billerica, MA, USA). Assay and cell counting were performed according to the instructions
supplied by the manufacturer. Samples were collected after the treatment and washed in PBS. For
analysis, 5 × 105 cells were resuspended in 200µL of Muse Cell Cycle Reagent, incubated for 30
min at room temperature, and the cell suspension was transferred to a 1.5 mL microcentrifuge tube
prior to analysis. Cells were analyzed by fluorescence-activated cell sorting analysis using a Muse
Cell Analyzer.
4.2.4. Effects on Apoptosis
Apoptosis assays on K562 cells were performed with the Muse Cell Analyzer instrument, and
assays were performed according to the instructions supplied by the manufacturer. The Muse Annexin
V & Dead Cell Kit employs annexin V to detect phosphatidyl serine (PS) on the external membrane of
apoptotic cells. A fluorescent DNA intercalator (7-ADD: 7-aminoactinomycin D) is also used as an
indicator of cell membrane integrity. From live, healthy cells, as well as early apoptotic cells, 7-ADD is
excluded while it is able to bind DNA in cells in late apoptosis and in dead cells. Cells were washed
with sterile PBS 1X, suspended, and diluted (1:2) with the Muse Annexin V & Dead Cell reagent.
Samples were gently mixed and incubated at room temperature, protected from the light for 15 min.
Samples were analyzed using a Muse Cell Analyzer, and data from prepared samples were acquired
and recorded utilizing the Annexin V and Dead Cell Software Module (Millipore) [61].
4.2.5. Molecular Modeling Methods
All molecular docking studies were performed on a Viglen Genie Intel®CoreTM i7-3770 vPro
CPU@ 3.40 GHz x 8 running Ubuntu 18.04. Molecular Operating Environment (MOE) 2019.10 [62] and
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Maestro (Schrödinger Release 2019-3) [54] were used as molecular modeling software. The tubulin
structure was downloaded from the PDB data bank (http://www.rcsb.org/; PDB code 4O2B). The
protein was preprocessed using the Schrödinger Protein Preparation Wizard by assigning bond orders,
adding hydrogens and performing a restrained energy minimization of the added hydrogens using
the OPLS_2005 force field. Ligand structures were built with MOE and then prepared using the
Maestro LigPrep tool by energy minimizing the structures (OPLS_2005 force field), generating possible
ionization states at pH 7 ± 2, generating tautomers and low-energy ring conformers. After isolating a
tubulin dimer structure, a 12 Å docking grid (inner-box 10 Å and outer-box 22 Å) was prepared using
as centroid the co-crystallized colchicine. Molecular docking studies were performed using Glide SP
precision, keeping the default parameters and setting 5 as the number of output poses per input ligand
to include in the solution. The output database was saved as a mol2 file. The docking results were
visually inspected for their ability to bind the active site.
5. Conclusions
In conclusion, we have described the synthesis and biological evaluation of two classes of
compounds based on the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine and 4,5,6,7-tetrahydrobenzo[b]thiop
hene skeletons, both characterized by the presence of a common 3′,4′,5′-trimethoxyanilino moiety
at the 2-position and a cyano or different alkoxycarbonyl groups at the 3-position. In the series of
2-(3′,4′, 5′-trimethoxyanilino)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivatives, the results indicated
that inhibition of cell growth was strongly dependent on the substituent at the 3-position, with the
greatest activity occurring with the cyano group, the least with alkoxycarbonyl moieties such as
methoxy/ethoxy/tert-butoxycarbonyl. We also demonstrated that replacement of the 4,5,6,7-tetrahydro
thieno[2,3-c]pyridine moiety with a 4,5,6,7-tetrahydrobenzo[b]thiophene system was detrimental for
antiproliferative activity. The 2-(3′,4′,5′-trimethoxyanilino)-3-cyano-6-methoxycarbonyl-4,5,6,7-tetrahy
drothieno[2,3-c]pyridine derivative 3a and the corresponding 6-ethoxycarbonyl homologue 3b were
the most promising compounds in this series, which inhibited cancer cell growth at low micromolar
concentrations and interacted with tubulin by binding to the colchicine site. Comparing the two
4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carbonitrile derivatives 3a and 3b, the latter was about
1.5-fold more active than 3a against L1210 and HeLa cells, while both these derivatives were equipotent
against CEM cells. We also showed by flow cytometry that derivatives 3a and 3b had cellular effects
typical of agents that bind to tubulin, causing accumulation of cells in the G2-M phase of the cell
cycle. Apoptotic cells also increased in a concentration-dependent manner, with an increase in
the percentage of apoptotic K562 cells observed at the IC50 values examined for 3a and 3b (0.75
and 0.70 µM, respectively). Finally, the same compounds showed high sensitivity towards cancer
over normal cells as they had no significant antiproliferative activity toward both quiescent and
phytohemoagglutinin-stimulated cultures of PBMC (IC50 > 20 µM), suggesting that derivatives 3a and
3b may have selectivity against cancer cells.
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